Question 1

What does PT-141 do?

Accepted Answer

PT-141 (bremelanotide) does one thing that a regulator has agreed it does. In 2019 it was approved in the USA for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty. That sentence is the whole of the approved claim, and every number further down this page sits either inside it or outside it. It does not act on blood flow. Melanocortins are endogenous neuropeptides associated with the excitatory pathway of the female sexual response system, so the compound works on a brain pathway rather than on the vessels of the genitals. What the trials counted follows from that. The responder analyses were performed for the change from baseline to end of study for a total of 7 endpoints, and all seven were questionnaire answers given by the patients themselves. No imaging, blood test or physical measurement appears anywhere in the efficacy record.

Question 2

What are the benefits of PT-141 for women?

Accepted Answer

This is where the whole evidence base sits, and it is narrower than it first looks. A 2026 systematic review of options for female sexual dysfunction pooled the controlled data it could find and concluded that bremelanotide improves both desire and arousal; and all 3 treatments reduce distress. Desire, arousal and distress are the three outcomes with pooled trial data behind them, and nothing else was measured often enough to pool. Everyone counted in that work carried a diagnosis. Of the 1,267 women randomized, 1,247 and 1,202 were in the safety and efficacy (modified intent-to-treat) populations, respectively, and each of those patients was premenopausal and had been assessed as having acquired, generalized hypoactive sexual desire disorder. Someone with ordinary fluctuating desire and no diagnosis was never enrolled in any of it. That is a different question rather than a milder version of the same one, and the trials answer only the first.

Question 3

Does PT-141 increase sexual desire?

Accepted Answer

Desire is the outcome the whole programme was built around, and it has the clearest answer on this page. Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder, which is the conclusion the Phase 3 trial authors drew from their own data. A later integrated analysis of the same patients adds that bremelanotide was further associated with statistically significant increases in reported sexual desire. What moved was a score rather than a behaviour. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13 for bremelanotide versus placebo. So the finding is that patients rated their own desire higher at the end than at the start, by more than the placebo group did over the same weeks. How large the gap was, and what two published re-analyses make of its size, is covered on our PT-141 hub page.

Question 4

Does PT-141 reduce the distress of low desire?

Accepted Answer

Distress was the second of the two main endpoints, and it rests on a single question. Item 13 of the Female Sexual Distress Scale asks how much a patient is bothered by low desire, and that one answer carried half the weight of the whole programme. The responder work beneath the Phase 3 trials set a threshold for it alongside FSDS-DAO item 13 and 14 scores, and number of satisfying sexual events, so that a change could be called meaningful rather than merely countable. The pooled result pointed one way. A 2020 review of the approval reports that bremelanotide demonstrates significant improvement in desire and a significant decrease in distress related to lack of desire. Both of those statements describe an average across patients in a trial. Neither tells a reader how often the bother fell away altogether, or how many people finished still bothered by the same amount, and an average cannot answer either question.

Question 5

Does PT-141 improve arousal?

Accepted Answer

Arousal is a separate outcome from desire, and much less was built to measure it. The 2026 review found enough data to pool arousal too, which puts it on the same footing as desire in that one result. Meta-analyses were conducted for mindfulness-based CBT, flibanserin, and bremelanotide, where CBT means talking therapy. Three options were pooled one at a time in a single paper, not run against each other. The trials aimed at arousal itself are older and mostly unreported. A Phase 2 study of PT-141 in Women With Female Sexual Arousal Disorder (FSAD) is marked COMPLETED on the trial registry, and no result for it has appeared in print. The later Phase 3, Bridging trial enrolled patients who had the desire diagnosis, With or Without Decreased Arousal, which folds arousal into that diagnosis rather than aiming at it. So the pooled arousal finding rests on trials built around desire, and that is not the same as a trial built to move arousal.

Question 6

Did PT-141 increase satisfying sexual events?

Accepted Answer

This is the outcome closest to something a person would notice, and it carries the smallest number on the page. In the dose-finding trial, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month for the pooled higher amounts against placebo. That is roughly one extra satisfying event every two months, averaged across a group, and efficacy data, n = 327 patients were needed to see it over twelve weeks. The same trial reported larger movements on the questionnaires. Mean changes were +3.6 versus +1.9 female sexual function index total score, and -11.1 versus -6.8 female sexual distress scale-desire/arousal/orgasm total score. Put those beside the event count and a pattern runs through the whole programme: the rated scores move further than the counted events do. Which of the two matters more to a particular person is a judgement rather than a finding, and no trial among the research behind this page has tried to settle it.

Question 7

How many women in the trials actually responded?

Accepted Answer

Group averages hide the shape of a result, so the programme asked how many individual patients crossed a threshold worth crossing. For all 7 endpoints, responder rates at the 1.75 mg dose achieved statistical significance compared with placebo (P ≤ .03), counted across everyone who had been randomised. More patients on the compound crossed the line than on placebo, on every measure tested. Two limits sit inside that answer. The thresholds were set partly by judgement: outcomes matched those based on input from clinical experts, which anchors a meaningful change to what clinicians thought it should be. And the ceiling was the placebo effect itself, since MCIDs for this study were based on changes from a single-blind phase to account for changes due to the placebo effect. A responder rate built that way describes how a trial population behaved against its own comparison group. It does not tell a reader what share of people outside that population would notice anything.

Question 8

Do the PT-141 efficacy scores measure anything real?

Accepted Answer

Every benefit above is a questionnaire score, so it is fair to ask what those scores are worth. A 2024 paper examined exactly that and found the instruments have questionable, at best, validity evidence for women with HSDD. The two it names are the desire domain and the distress item, which were the main endpoints of the Phase 3 trials. The same authors go further on the responder question. They found no validity evidence for previously published categorical treatment response outcomes from the RECONNECT trials, which is the step that turns a score change into a person who got better. A separate 2021 re-analysis of the same trials records that no secondary outcome had a stated rationale or cited evidence of validity. None of this makes the approval wrong, and none of it says nothing happened. It means the benefit rests on scales that were never shown to measure what they are read as measuring.

Question 9

Does the benefit from PT-141 last?

Accepted Answer

The longest look is a 52-week open-label extension, in which everyone knew what they were receiving. Of the 856 eligible patients who completed the core phase, 684 elected to participate in the open-label extension, and 272 completed it, so fewer than half of the people who started the extension reached the end of it. That drop-off is part of the result rather than a footnote beneath it. For the patients who stayed, the scores held. The change in Female Sexual Function Index-desire domain score and Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 from baseline to end of the open-label extension ranged from 1.25 to 1.30 and -1.4 to -1.7, respectively, for patients who received bremelanotide during the core phase. Two cautions apply at once: all statistical analyses were descriptive, and there was no blinded comparison group running alongside, so a year of open-label scores cannot separate a lasting effect from a lasting expectation.

Question 10

Did PT-141 work the same for everyone in the trials?

Accepted Answer

The subgroup analysis is the closest the record comes to a personal answer, and it is blunter than that sounds. The authors split the Phase 3 patients by prespecified subgroups (age, weight, body mass index [BMI], and bioavailable testosterone) and ran the same test inside each slice. Across those slices of patients, bremelanotide was associated with statistically significant improvements in sexual desire and reduced distress, with few exceptions. In plain words, the result did not hang on being younger, lighter or higher in testosterone. A subgroup analysis compares averages between parts of one trial, so it cannot pick out the person who will respond. Every part was cut from the same enrolled group, because these analyses were restricted to a study population composed only of premenopausal women with the diagnosis. Outside that group there is no subgroup at all. Men, postmenopausal women and anyone with low desire but no diagnosis were never enrolled, so the data is silent about them rather than thin about them.

Question 11

What are the benefits of PT-141 for men?

Accepted Answer

Nothing on this page was measured in men. The published record for men stops in the mid-2000s. A 2004 report describes a plan to develop it as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction, and notes that in February 2004, Palatin planned to start phase III trials in early 2005. Those trials in men never produced a published result. The reviews from that era describe an intention rather than a finding. A 2006 survey of the melanocortin peptides states only that PT-141 may improve sexual functionality in both males and females. A 2014 review of the same field, written after the male work had stopped, ends by saying the data warrant further investigation to demonstrate the impact of the activation of MCRs by specific agonists on penile erection. MCRs there are melanocortin receptors, the brain targets this compound binds. Twenty years on, the female half of that sentence produced an approval and the male half produced nothing, which is an absence where a result should be rather than a weaker version of the female evidence.

Question 12

Does PT-141 help erectile dysfunction?

Accepted Answer

PT-141 was built for erectile dysfunction, and the work was never finished. A 2025 review of the field still lists it among the candidates, covering peptide and amino acid therapies for ED, focusing on PT-141, PnPP-19, L-arginine, and L-citrulline. Being named as a candidate twenty years after a Phase 2b trial shows continued interest rather than added evidence. The reason anyone kept looking is the route it takes. It belongs to a small family of melanocortin receptor (MCR) agonists (melanotan I, melanotan II, bremelanotide), which act on a brain pathway rather than on the blood vessels that the familiar tablets work on. A 2026 review of peptides groups compounds by what they are used for, and files this one under sexual function (bremelanotide). None of that is a measured outcome in a man. No trial among the research behind this page has set PT-141 against a standard option for ED in patients, so there is no basis for putting either one ahead.

Question 13

Does PT-141 raise libido without a diagnosis?

Accepted Answer

Every trial required a diagnosis, so this question has no direct answer, and the diagnosis is not a formality. A 2021 overview defines it as a deficiency of sexual thoughts, feelings, or receptiveness to sexual stimulation that has been present for at least 6 months, causes personal distress. Six months, real distress, and no other condition behind it. Every patient in the efficacy record had cleared all three bars before being enrolled. Low desire without that picture was never studied, which makes it a different group rather than a milder slice of the one that was. A 2025 review of options for women frames the work as patient selection, expectation setting, side effect management, and patient education, with the fit to the patient named ahead of the choice of compound. The plainest summary came with the approval itself: bremelanotide's place in therapy is unknown, as the HSDD guidelines were last updated in 2017.

Question 14

Is PT-141 the most effective peptide for female arousal?

Accepted Answer

No compound in this area has been tested against another in a head-to-head trial, so the question cannot be answered the way it is asked. The nearest thing is the 2026 review, which pooled several options one at a time, and that review states plainly that no studies directly compared CBT to pharmacotherapy. Pooling three options in one paper is not the same as running them against each other in the same patients. Two things follow from that. PT-141 is the only peptide in that pooled comparison, so ranking peptides for arousal means setting one studied compound beside others that have never been through a controlled trial for it. And a rank needs a yardstick that nothing we cite has built: conclusions regarding most other treatments could not be drawn due to limited numbers of studies of FSD excluding pain, heterogeneous terminology for DAO disorders, and varying outcome measures across studies. DAO there stands for desire, arousal and orgasm. Until two of them are given to similar patients in one trial, any ordering is a preference rather than a finding.

Question 15

Does PT-141 do anything for orgasm?

Accepted Answer

Orgasm is the third outcome this field measures, and it is the one with nothing attached. The 2026 review set its own scope around desire, arousal, and/or orgasm (DAO) in women, then reported pooled findings for desire and for arousal only. Orgasm was inside the question and missing from the answer. Part of the reason is what went unreported. A 2024 analysis dug out trial outcomes that had never appeared in print, and found that 8 of the 11 clinicaltrials.gov-specified efficacy outcomes were heretofore unpublished. When those were analysed, effect sizes ranged from nil to small. A 2021 re-analysis makes a related point about picking, noting that the first authors provided results of 15 secondary measures which were not listed in the study protocols. Silence about orgasm is therefore weak evidence in either direction. It is a missing measurement rather than a measured absence.

PT-141: what the research measured